The paper, authored by researchers at the University of Illinois Chicago, the University of Chicago, and the University of Miami Health System, proposes a lifespan framework for women’s health in sickle cell disease that stretches from menarche through menopause and into healthy aging. Its central claim is provocative: while fertility and pregnancy have received increasing attention as patients survive longer, menopause remains an underexplored and underrecognized phase of the disease trajectory, one that may shape pain, cognition, bone strength, cardiovascular risk, iron burden, and quality of life for decades.

To understand why menopause matters so much in this population, it helps to revisit the biology. Sickle cell disease stems from a single nucleotide substitution in the beta-globin gene that produces hemoglobin S. Under low-oxygen conditions, this hemoglobin polymerizes, forcing red blood cells into rigid, crescent shapes. These sickled cells are less deformable, stick to the vascular endothelium, and clog small vessels, producing the hallmark vaso-occlusive pain crises. Repeated sickling also damages cell membranes, driving chronic hemolysis, which in turn depletes nitric oxide, fuels oxidative stress, and sustains endothelial dysfunction and inflammation. The result is a multisystem disorder in which overlapping mechanisms inflict cumulative organ injury beginning in childhood.

That cumulative injury has led some researchers to describe sickle cell disease as a form of accelerated biological aging. The lungs are vulnerable to acute chest syndrome, pulmonary embolism, and pulmonary hypertension. Kidney damage can begin with tubular dysfunction in childhood and progress to chronic kidney disease in adolescence and adulthood. Cerebrovascular injury, from silent cerebral infarction to overt stroke, erodes cognition and quality of life. Against this backdrop, the authors argue, reproductive aging is not a separate process but another manifestation of aging that deserves a place alongside the rest.

Female physiology adds further layers of complexity. Although the disease arises from a single mutation, its severity is modified by genetics, including variants regulating fetal hemoglobin such as those affecting BCL11A, co-inherited alpha-thalassemia, APOL1 kidney risk variants, and pathways involved in oxidative stress and inflammation. Environmental exposures such as air pollution, secondhand smoke, and psychosocial stress worsen outcomes. And female-specific states modulate disease directly: menstruation can precipitate vaso-occlusive pain episodes beginning at menarche, hormonal fluctuations across the cycle influence vascular tone and inflammatory balance, hormonal contraceptives may alter thrombotic risk, and pregnancy, with its increased oxygen demand and prothrombotic state, amplifies the underlying vasculopathy.

Historically, clinical attention to reproduction in sickle cell disease has clustered around two moments: preserving fertility and managing pregnancy. Both matter. Hypoxic-ischemic injury, chronic inflammation, and gonadal exposure to disease-modifying therapies or transplant conditioning can diminish ovarian reserve. Pregnancy carries heightened risks of vaso-occlusive complications, acute chest syndrome, thromboembolism, preeclampsia, and medically indicated preterm delivery, and treatment decisions during pregnancy remain hampered by gaps in evidence. But the authors contend that this framing treats reproductive health as a series of isolated episodes rather than a continuous life course, and that the continuum does not end with pregnancy. It transitions into midlife, where the evidence is thinnest.

What evidence exists suggests that menopause arrives early. A Brazilian cohort reported menopause roughly five years earlier than expected in the general population, at approximately 46 to 48 years of age, and more recent observational studies from U.S. cohorts have similarly reported mean ages in the mid-to-late forties. These findings come with heavy caveats: small samples, single-center designs, and retrospective data collection that invites recall bias. Larger prospective studies are needed to determine whether reproductive aging is consistently accelerated, and whether timing differs by genotype, disease severity, or treatment exposure. Still, the signal is strong enough that the authors argue menopause should be treated as a critical component of comprehensive sickle cell care.

The midlife picture is more complicated than a simple worsening. In one cohort, up to 80 percent of women reported a reduction in vaso-occlusive pain frequency after menopause, raising the possibility that hormonal changes influence pain pathways, though the authors caution this should not be read as evidence that menopause consistently improves disease-related pain. Meanwhile, vasomotor symptoms, sleep disturbance, mood changes, anxiety, and fatigue may emerge or intensify during the transition, and because many of these overlap with core manifestations of sickle cell disease, menopause-related morbidity risks being misattributed entirely to the underlying condition, leading to underdiagnosis and undertreatment.

Treatment raises its own unresolved questions. Menopausal hormone therapy is the most effective treatment for vasomotor symptoms and has established indications for women with premature or early menopause, but there are currently no adequately powered clinical trials evaluating its safety, efficacy, or optimal formulation and duration in women with sickle cell disease. Because the disease is characterized by endothelial dysfunction, inflammation, and a prothrombotic state, thrombosis is an obvious concern, yet the authors stress that whether hormone therapy adds clinically meaningful thrombotic risk in this population has not been established; it is an important clinical question, not a demonstrated contraindication. Genitourinary syndrome of menopause, with its vaginal dryness, dyspareunia, and urinary symptoms, is another likely under-recognized burden, and low-dose vaginal estrogen, which has minimal systemic absorption, has not been evaluated in these patients.

Beyond symptoms, menopause may intersect with organ systems already compromised by the disease. Estrogen decline accelerates bone resorption, compounding skeletal vulnerability from chronic inflammation, marrow hyperplasia, vitamin D deficiency, and delayed puberty. Cessation of menstruation eliminates a physiologic route of iron loss, and emerging observations suggest iron indices may rise after menopause even after accounting for transfusion history, a particular concern for women with transfusion exposure. Cognitive health presents perhaps the most striking intersection: women with sickle cell disease may enter the menopausal transition carrying pre-existing neurovascular vulnerability from chronic anemia, cerebral hypoxia, and silent infarcts, so midlife hormonal changes unfold under far higher neurological risk than in the general population. Frailty and functional decline, the authors hypothesize, may likewise accelerate when menopause-related changes land on decades of disease-related physiologic stress.

The equity dimensions are hard to ignore. Sickle cell disease disproportionately affects populations in sub-Saharan Africa, the Middle East, India, and parts of the Americas, precisely the regions where access to comprehensive chronic disease management, reproductive health services, and menopause care is most variable. Even in resource-rich settings, care is fragmented between hematology, obstetrics, gynecology, and primary care; menopause may fall outside hematologists’ traditional scope, while menopause clinicians may have little experience with the disease. In low- and middle-income settings, structured menopause care may be entirely absent from routine services, meaning women enter midlife without any systematic assessment of symptoms or surveillance for bone, cardiovascular, cognitive, and functional decline.

The authors’ prescription is a coordinated lifespan model: routine screening for menstrual changes, vasomotor symptoms, sleep, mood, fatigue, genitourinary symptoms, and sexual health as women approach midlife; careful attribution of new or changing symptoms to both disease and menopause rather than defaulting to the disease alone; individualized hormone therapy decisions weighing genotype, prior venous thromboembolism, and vascular risk; and referral pathways connecting sickle cell specialists with menopause expertise. They also call for research priorities spanning prospective cohorts tracking age at menopause, genotype-stratified analyses, trials of menopause therapies, cognitive and neuroimaging studies, and implementation research adapted to local resources rather than assuming one multidisciplinary model fits all settings.

The stakes extend beyond any single clinic. As survival improves, the measure of success for a lifelong genetic disease can no longer be simply keeping children alive; it must be whether those children grow into adults who age well. Integrating reproductive aging into clinical practice, research agendas, and health policy, the authors argue, is an opportunity to strengthen women-centered care and advance health equity for the millions of women worldwide living with sickle cell disease. Menopause, long invisible in the sickle cell literature, may turn out to be one of the most consequential frontiers in the field.

Subject of Research: Menopause and reproductive aging in women with sickle cell disease across the lifespan

Article Title: From menarche to menopause: a lifespan perspective on women's health in sickle cell disease

Article References: Farooqui, M., Christmas, M., Goba, G., & Hsu, L. (2026). From menarche to menopause: a lifespan perspective on women's health in sickle cell disease. Frontiers in Epidemiology, 6, Article 1931488. https://doi.org/10.3389/fepid.2026.1931488

Image Credits: AI Generated

DOI: 10.3389/fepid.2026.1931488

Keywords: sickle cell disease, menopause, women's health, reproductive aging, menopausal hormone therapy, vaso-occlusive pain, health equity, bone health, cognitive health, iron overload, cardiovascular risk, lifespan care

The study, conducted by Susanne Mitschke of Harvard T.H. Chan School of Public Health, recruited 226 perimenopausal or postmenopausal participants aged 45 to 65 through online health forums, social media platforms, menopause support groups, and email newsletters between July 21 and August 12, 2024. All participants reported experiencing menopausal or perimenopausal symptoms, and women with a history of breast cancer, heart disease, or blood clots were excluded because those conditions are established contraindications to hormone therapy. The survey, administered through the Qualtrics platform, took a median of 2.8 minutes to complete and captured sociodemographic characteristics, supplement use, perceived effectiveness, information sources, and perceptions of menopausal hormone therapy, commonly abbreviated MHT.

The headline numbers reveal a striking gap between general supplement consumption and symptom-targeted use. Current use of at least one dietary supplement for any purpose was reported by 138 participants, or 61.1 percent of the sample, with a 95 percent confidence interval of 54.6 to 67.2 percent. But when asked directly whether they were using supplements to manage menopause symptoms, only 65 participants, or 28.9 percent, answered yes. Of the 138 current supplement users, 72 answered no to the menopause-specific question, indicating that their supplement use was driven by motivations other than symptom relief. The two survey items, the study notes, measure different constructs and should not be read as bounds on a single quantity.

The product profile among users further underscores this distinction. Multivitamins led the list at 55.8 percent of supplement users, followed by vitamin D at 52.9 percent, magnesium at 51.4 percent, and probiotics at 41.3 percent. By contrast, botanical products with a more menopause-specific evidence base, such as black cohosh, soy isoflavones, red clover, and evening primrose oil, were reported far less frequently. Black cohosh, for instance, was used by just 10.1 percent of supplement users, while soy isoflavones and St. John’s Wort each registered at 1.4 percent. Notably, participants who reported menopause-targeted use were significantly more likely to take black cohosh, any herbal or botanical product, and probiotics, whereas general users more often reported multivitamins and calcium, products typically associated with overall health maintenance or bone support.

Usage patterns among supplement users were remarkably consistent. Of the 110 users who answered the duration question, 53.6 percent had been taking supplements for more than a year, and of the 125 who answered the frequency question, 88.8 percent reported daily use. Users reported a median of three supplement types. Yet perceived effectiveness was decidedly mixed: among the 115 users who rated their supplements, 47.0 percent described them as somewhat or very effective, 27.8 percent were neutral, and 25.2 percent rated them as somewhat or very ineffective. Perceived effectiveness was significantly higher among those using supplements specifically for menopause symptoms, at 56.2 percent, compared with 35.3 percent among general users, a difference the study suggests may simply reflect that the latter group was not seeking symptom relief in the first place.

On the hormone therapy front, awareness was high but enthusiasm tempered by lingering fears. Some 82.7 percent of participants were aware of MHT, and 11.5 percent were currently using it. Perceptions leaned neutral or positive, with 45.1 percent neutral and 36.7 percent somewhat or very positive. However, concerns about specific risks were widespread: 47.8 percent cited increased breast cancer risk, 44.7 percent cited blood clotting, 40.7 percent cited stroke, and 37.2 percent cited heart disease. Only 36.3 percent reported no concerns at all. These figures echo the enduring influence of the initial Women’s Health Initiative findings, even though subsequent analyses have nuanced the original results, suggesting that for women younger than 60 or within 10 years of menopause onset without contraindications, the benefits of MHT often outweigh the risks.

The study also uncovered significant demographic disparities in MHT awareness. Awareness rose monotonically with income, reaching 100 percent among participants earning $200,000 or more, compared with 66.2 percent among those earning less than $50,000. Awareness was lowest among participants identifying as Black or African American, at 38.5 percent, those with a high school diploma or GED, at 69.2 percent, and current smokers, at 67.6 percent. Current MHT use was associated with income alone, ranging from 4.2 percent among the lowest earners to 33.3 percent among the highest. Because several racial and ethnic groups were represented by very few participants, the authors caution that these comparisons rest on small numbers and call for larger, more diverse studies to confirm the patterns.

In the multivariable logistic regression, smoking status emerged as the only participant characteristic significantly associated with any supplement use. Former smokers had 2.98 times the odds of supplement use compared with current smokers, and never smokers had 3.92 times the odds, with the overall smoking effect reaching statistical significance at p equals 0.012. Participants aged 61 to 65 also showed higher odds, though that estimate was based on just 17 users and 2 non-users and carried a correspondingly wide confidence interval. Critically, when the analysis was repeated with menopause-targeted use as the outcome, none of the covariates was associated with the result, suggesting the smoking association reflects general wellness-oriented behavior rather than menopause-specific self-treatment. The overall model explained little of the variation in supplement use, with a McFadden pseudo-R-squared of just 0.075.

Information-seeking patterns revealed a clear hierarchy of trust. Healthcare providers were the most commonly cited source of information about menopause symptom management, at 69.0 percent of all participants, closely followed by the internet, online articles, blogs, and websites at 67.7 percent. When asked to rate trustworthiness on a scale, 75.3 percent of those rating healthcare providers judged them trustworthy or extremely trustworthy. Social media influencers, by contrast, were rated extremely untrustworthy by 47.1 percent of the 206 respondents who evaluated that source, making them the least trusted information channel by a wide margin. Among supplement users themselves, personal research was the leading factor influencing product choice at 42.5 percent, followed by recommendations from healthcare providers at 29.2 percent, while social media influencers and marketing each influenced just 0.9 percent of users.

The authors are careful to frame the findings within the study’s limitations. The voluntary response sampling means the prevalence estimates describe a self-selected sample of women with a particular interest in menopause and wellness, not the broader population of midlife women. The sample was also predominantly white, at nearly 80 percent, and highly educated, with 87.6 percent holding credentials above a high school diploma. The questionnaire was developed for the study and not formally validated, and it did not measure symptom severity with a validated instrument or distinguish perimenopausal from postmenopausal participants. Because the supplement list item did not ask the purpose of each product, the study cannot establish which specific supplements were taken exclusively for menopause symptoms. Despite these constraints, the findings highlight a clear clinical imperative: healthcare providers, who remain the most trusted source of information, have a significant opportunity to proactively ask about supplement use, provide balanced counseling on both evidence-based hormone therapy and the heterogeneous evidence behind popular supplements, and help women make informed, individualized decisions about managing this consequential life transition.

Subject of Research: Dietary supplement use and perceptions of menopausal hormone therapy among symptomatic menopausal women aged 45 to 65

Article Title: Dietary supplements are commonly used for menopause symptoms amid concerns about hormone therapy: a cross-sectional study

Article References: Mitschke, S. (2026). Dietary supplements are commonly used for menopause symptoms amid concerns about hormone therapy: a cross-sectional study. Frontiers in Global Women's Health, 7, Article 1924461. https://doi.org/10.3389/fgwh.2026.1924461

Image Credits: AI Generated

DOI: 10.3389/fgwh.2026.1924461

Keywords: menopause, dietary supplements, menopausal hormone therapy, women's health, black cohosh, vitamin D, magnesium, probiotics, Women's Health Initiative, cross-sectional study, health information sources, perimenopause

The Women’s Health Initiative enrolled postmenopausal women aged 50 to 79 years at 40 United States clinical centers between 1993 and 1998 in two randomized, double-blind, placebo-controlled trials. Women with a uterus, numbering 16,608, were assigned to daily oral conjugated equine estrogen at 0.625 milligrams per day plus medroxyprogesterone acetate at 2.5 milligrams per day, or to matching placebo. Women who had undergone hysterectomy, numbering 10,739, were randomized to estrogen alone or placebo. Assignment used a centralized permuted-block algorithm stratified by clinical center, age group, and hysterectomy status, and blinding was maintained with identical-appearing tablets. The estrogen-plus-progestin trial was stopped early in 2002 after 5.6 years because overall health risks outweighed benefits, while the estrogen-alone trial stopped in 2004 after 7.2 years because of increased stroke risk without a clear coronary benefit.

Because liver cancer was not a protocol-specified outcome, the investigators treated the new analysis as a secondary examination, following participants through December 31, 2023. All incident cancers, including liver cancers, were confirmed by central medical record review conducted by adjudicators blinded to randomization assignment. Mortality information was near complete at 98 percent, thanks to serial queries of the National Death Index through 2023. Statistical analysis followed the intention-to-treat principle, using Cox proportional hazards models stratified by age group, dietary modification trial randomization, and study period, with two-sided stratified log-rank tests to compare groups.

A total of 74 incident primary liver cancers were identified across both trials, 26 in the estrogen-alone trial and 48 in the combined-therapy trial. In the estrogen-alone trial, with median cumulative follow-up of 16.3 years for incidence, the hormone arm showed no significant difference from placebo: 11 cancers versus 15, corresponding to an annualized rate of 0.012 percent versus 0.016 percent, and a hazard ratio of 0.75 with a 95 percent confidence interval of 0.34 to 1.63. The result was unchanged after adjustment for bilateral oophorectomy status, and there was no evidence that the proportional hazards assumption was violated.

The combined-therapy trial told a more textured story. Over 19.5 years of cumulative follow-up, women assigned to estrogen plus progestin experienced 30 liver cancers compared with 18 in the placebo group, an annualized rate of 0.019 percent versus 0.012 percent, yielding a hazard ratio of 1.63 with a confidence interval of 0.91 to 2.92, which just missed conventional significance. Crucially, the analysis detected evidence of non-proportional hazards, meaning the treatment effect changed over time. During the intervention phase itself, the hazard ratio was 0.66, but in the post-intervention period it rose to 2.11 with a confidence interval of 1.06 to 4.18, statistically elevated. In other words, the excess liver cancer risk emerged years after women had stopped taking the pills.

Subgroup analyses, restricted to the combined-therapy trial because of limited events elsewhere, sharpened the signal. Women aged 50 to 59 years at randomization who received the combined therapy developed 10 liver cancers, while none occurred in their placebo counterparts, a trend with a P value of 0.01. Prior users of oral contraceptives randomized to the combined regimen faced a hazard ratio of 4.30, with a confidence interval of 1.46 to 12.72 and a significant interaction test. Excess cases appeared among younger women both with and without prior oral contraceptive use, and the association was not explained by adjustment for contraceptive history. Current drinkers showed a somewhat stronger association, particularly those consuming one or more drinks per week, though the interaction test was not significant. No consistent effect modification was seen by smoking, body mass index, or prior menopausal hormone therapy.

The authors urge caution in interpreting these subgroup findings. Age and oral contraceptive use were not randomized variables, so they identify possible treatment-effect heterogeneity rather than causal mechanisms. Chance remains a serious consideration: liver cancer was not a protocol-specified endpoint, the overall effect was not statistically significant, and the findings rest on a modest number of events. Recent large prospective data and meta-analyses do not support a strong association between ever use of oral contraceptives and liver cancer risk, and the concentration of cases among contraceptive users does not establish an additive hormonal burden. Nonetheless, the randomized signals may be valuable for guiding future cohort studies and meta-analyses.

What makes the trial results so striking is how sharply they diverge from the observational literature. A 2016 systematic review and meta-analysis of 1,795 liver cancer cases reported roughly 40 percent lower risk among menopausal hormone therapy users, with a relative risk of 0.60. A United Kingdom nested case-control study using the Clinical Practice Research Datalink and a recent Swedish population-based cohort similarly reported 30 to 60 percent lower liver cancer risk among hormone therapy users. The neutral overall Women’s Health Initiative estimate, and the directionally unfavorable combined-therapy finding, stand in direct contrast to these reports.

This discordance echoes a familiar pattern in hormone therapy research. Observational cohort studies suggested cardiovascular benefit from menopausal hormone therapy, yet the randomized trials found no coronary heart disease prevention and early harm with the combined regimen. Cohort studies linked estrogen-alone therapy to higher breast cancer incidence, while the randomized trials showed significantly lower breast cancer incidence and mortality with estrogen alone. The discrepancies likely reflect self-selection of healthier women who initiate hormone therapy, and depletion of susceptible women who develop early outcomes or discontinue because of intolerable side effects. Randomized assignment, double blinding, and central adjudication of outcomes eliminate these biases. Notably, United States population trends after the sharp decline in hormone therapy use following 2002, including lower breast and ovarian cancer incidence and higher endometrial cancer incidence, have been consistent with the randomized evidence rather than the observational findings.

Mechanistically, the picture remains unsettled. Experimental models suggest that estrogen can protect the liver through anti-inflammatory pathways, including suppression of interleukin-6 via estrogen receptors on Kupffer cells, the liver’s resident macrophages, which could help explain why women develop liver cancer less often than men. Estrogen and progestin signaling can also exert tissue- and pathway-specific effects, and prior Women’s Health Initiative results have differed by formulation, with the addition of medroxyprogesterone acetage offsetting estrogen-alone effects on endometrial, ovarian, and breast cancers, possibly through apoptotic mechanisms. Formulation-specific liver cancer findings are therefore biologically plausible, even if the event numbers here are too small for firm inference. Known viral and non-viral risk factors for liver cancer, including chronic hepatitis, cirrhosis, smoking, alcohol, obesity, diabetes, and thrombocytopenia, were well balanced across randomization groups, limiting residual confounding. The bottom line for clinicians and patients is clear: the randomized evidence argues against menopausal hormone therapy as a strategy for liver cancer prevention, while highlighting younger women and prior oral contraceptive users as subgroups that warrant closer study in future research.

Subject of Research: Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials

Article Title: Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials

Article References: Pichardo, M. S., Aragaki, A. K., Manson, J. E., Pan, K., Jung, S. Y., Rohan, T. E., Mszar, R., & Chlebowski, R. T. (2026). Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women’s health initiative randomized trials. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03621-9

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03621-9

Keywords: liver cancer, menopausal hormone therapy, Women's Health Initiative, estrogen, hepatocellular carcinoma, randomized trials, Menopausal, hormone, therapy, primary, liver, cancer

The study, published as an open-access research article in BMC Endocrine Disorders, drew on the Korea National Health and Nutrition Examination Survey, known as KNHANES, specifically the fourth wave conducted between 2007 and 2009. The investigators, led by Ziran Qiu of the Department of Breast and Thyroid Surgery at Loudi Central Hospital in Hunan, China, together with colleagues including corresponding author Na Jin, focused on postmenopausal women, a group in which both menopausal hormone therapy and thyroid disease converge with unusual frequency. Thyroid disorders, which range from underactive and overactive gland function to nodules and autoimmune inflammation, are markedly more common in women than in men, and their prevalence rises with age, making the postmenopausal population a natural setting for asking whether exogenous hormones tip the balance.

The analytical sample comprised 3,974 postmenopausal women, of whom 582 reported a history of using female hormone medication. The exposure was deliberately simple: a questionnaire item recording whether the participant had ever taken female hormone drugs. Importantly, the survey did not capture whether use was current, which formulation was taken, at what dose, or for how long, a limitation that shapes how the results can be interpreted. The outcomes were equally grounded in self-report: thyroid disorders diagnosed by a doctor served as the primary endpoint, while current thyroid disorder, lifetime thyroid disorder, and currently treated thyroid disorder served as secondary endpoints. This reliance on questionnaire-defined disease means the study measures the burden of recognized and recorded thyroid illness rather than laboratory-confirmed thyroid dysfunction in the moment.

The headline numbers are striking. Weighted prevalence of doctor-diagnosed thyroid disorder was 10.87 percent among women with a hormone therapy history versus 6.87 percent among women without one. Current thyroid disorder showed a similar gap, 6.79 percent versus 3.79 percent, as did lifetime thyroid disorder at 10.95 percent versus 6.96 percent and treated thyroid disorder at 4.88 percent versus 2.95 percent. In every case, women reporting prior hormone medication use carried roughly a one-and-a-half to nearly two-fold heavier burden of thyroid disease on the raw, survey-weighted scale.

Because raw differences in observational data can easily reflect age, body weight, income, reproductive history, or the simple fact of seeing doctors more often, the team turned to survey-weighted logistic regression, the standard tool for estimating associations in complex national surveys. Their models adjusted for demographic, socioeconomic, metabolic, reproductive, and survey-year factors. To guard against the statistical trap of cherry-picking significant results across multiple tests, they applied Benjamini-Hochberg correction, computing q values that control the expected proportion of false discoveries across the four outcomes. After adjustment, a history of female hormone therapy remained associated with doctor-diagnosed thyroid disorder with an adjusted odds ratio of 1.52 and a 95 percent confidence interval of 1.06 to 2.16, with a q value of 0.031. The estimate for current thyroid disorder was even stronger, at an odds ratio of 1.75 with a confidence interval of 1.09 to 2.83, and lifetime thyroid disorder yielded an odds ratio of 1.50 with a confidence interval of 1.06 to 2.14, both also surviving the false discovery correction at q equal to 0.031. The estimate for currently treated thyroid disorder was directionally similar but less statistically secure, at an odds ratio of 1.60 with a confidence interval spanning 0.96 to 2.68 and a q value of 0.071.

Recognizing that any single modeling choice can swing results, the researchers ran an unusually thorough battery of sensitivity analyses. When they expanded the covariate set further, the primary estimate attenuated to an odds ratio of 1.38 with a confidence interval of 0.96 to 2.00, no longer excluding the possibility of no association. When they adjusted for healthcare contact, an attempt to account for the possibility that hormone therapy users simply interact with the medical system more and therefore get diagnosed more often, the association held at an odds ratio of 1.46 with a confidence interval of 1.01 to 2.10. Restricting the analysis to narrower age bands, however, produced estimates that crossed the null, suggesting the signal may be sensitive to the age composition of the sample. Adding gravidity, the number of times a woman had been pregnant, to the adjustment left the estimate essentially unchanged at an odds ratio of 1.52 with a confidence interval of 1.05 to 2.20. Exploratory analyses of treatment duration returned heterogeneous results, offering no consistent picture of whether longer exposure carried greater risk.

What might connect ovarian hormone preparations and the thyroid gland biologically? The mechanistic story is plausible but unresolved. Estrogen influences thyroid physiology in several documented ways: it can stimulate thyroglobulin, the protein scaffold on which thyroid hormones are synthesized, and it modulates immune activity in a gland where autoimmune disease, particularly Hashimoto’s thyroiditis, is disproportionately common in women. Hormone therapy could also plausibly promote thyroid growth or nodule formation in a gland already rich in estrogen receptors. Conversely, the association could run in the opposite causal direction: women with thyroid symptoms such as fatigue, weight change, or mood disturbance might seek menopausal symptom relief through hormone therapy, or their thyroid conditions might simply be diagnosed around the same life stage. Residual confounding by health-seeking behavior, physician vigilance, or unmeasured metabolic traits remains a live possibility in any cross-sectional design.

The authors are explicit about the limits of their evidence. Because the exposure and outcomes were both self-reported and captured at a single point in time, the study cannot establish temporality, let alone causality. It cannot distinguish whether hormone therapy preceded the thyroid disorder, followed it, or merely co-occurred with it. The questionnaire also could not identify current users or treatment details, blurring any dose or duration effects. Yet the consistency of the association across three of four endpoints, its survival of false discovery correction, and its persistence under healthcare-contact adjustment give the finding enough weight that it should not be dismissed as statistical noise. At the same time, the attenuation under expanded adjustment and the null results in age-restricted analyses are honest reminders that the true effect, if any, is likely modest and context-dependent.

For clinicians and the millions of postmenopausal women weighing hormone therapy, the practical takeaway is one of measured vigilance rather than alarm. The study’s authors state plainly that their findings do not support universal thyroid screening for women with a hormone therapy history, nor do they justify changing menopausal hormone therapy decisions solely on the basis of that history. Standard practice, in which thyroid function is evaluated when symptoms or clinical findings warrant it, remains the appropriate course. What the research does provide is a well-powered, nationally representative East Asian data point in a literature long dominated by Western cohorts, and a clear template for the kind of study needed next: prospective, longitudinal designs with pharmacy-verified hormone exposure, laboratory-measured thyroid function, and careful sequencing of treatment and diagnosis. Until such evidence arrives, the association between hormone therapy history and thyroid disorder burden in postmenopausal Korean women stands as an intriguing signal, a question mark that modern endocrinology will now be pressed to resolve.

Subject of Research: The association between self-reported menopausal hormone therapy history and thyroid disorder prevalence among postmenopausal Korean women in the KNHANES IV survey.

Article Title: Self-reported female hormone therapy history and thyroid disorder burden among postmenopausal Korean women: a cross-sectional KNHANES IV study

Article References: Qiu, Z., Long, H., Li, R., Yang, J., Cao, W., Chen, S., & Jin, N. (2026). Self-reported female hormone therapy history and thyroid disorder burden among postmenopausal Korean women: a cross-sectional KNHANES IV study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02540-3

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02540-3

Keywords: menopausal hormone therapy, thyroid disorder, postmenopausal women, KNHANES, cross-sectional study, South Korea, endocrinology, odds ratio, thyroid screening, estrogen, women's health, observational study

A new systematic review and meta-analysis published in BMC Cancer has now brought the weight of all available evidence to bear on that question, and its conclusions are both reassuring and subtly intriguing. Led by Mohammad Amouzadeh-Lichahi, Maryam Jafari, Nazila Sattari, Sara Zamani, Negin Letafatkar and Shahriar Ghodous of Guilan University of Medical Sciences in Rasht, Iran, the research team systematically searched PubMed, Scopus and Embase for observational studies published up to July 2026. Their exhaustive sweep of the literature identified twenty-seven reports that met their rigorous inclusion criteria, covering the use of oral contraceptive pills, menopausal hormone therapy, estrogen therapy alone, and combined estrogen–progestin therapy in relation to pancreatic cancer risk. By pooling adjusted effect estimates across studies with random-effects models, the team aimed to produce the most definitive statistical picture to date of how these hormonal exposures relate to one of oncology’s deadliest cancers.

The methodological machinery behind the analysis was considerable. The researchers followed PRISMA reporting guidelines and evaluated study quality using the Newcastle–Ottawa Scale, while the certainty of the resulting evidence was graded with the GRADE framework. Heterogeneity among studies was quantified with the I-squared statistic, and publication bias was probed with both Egger’s and Begg’s tests. Crucially, the team went beyond simple pooled estimates: they computed ninety-five percent prediction intervals, which indicate the range of effects that might plausibly be expected in a future study conducted in a new population, and they performed both linear and non-linear dose–response meta-analyses to test whether longer durations of hormone use translated into progressively altered risk. This layered approach matters because a pooled relative risk alone can mask enormous variability in what individual studies actually find.

The headline result for oral contraceptives was, in statistical terms, a null finding. Across twenty studies, women who had used the pill showed a pooled relative risk of pancreatic cancer of 0.99, with a ninety-five percent confidence interval spanning 0.86 to 1.14 — a range that comfortably includes no effect. The prediction interval was strikingly wide, stretching from 0.62 to 1.59, and heterogeneity between studies was substantial at 61.4 percent. The GRADE assessment rated this evidence as very low certainty. In plain language, the analysis found no overall association between oral contraceptive use and pancreatic cancer, but the underlying studies disagreed with one another enough that the true effect in any given population could conceivably fall anywhere between a meaningful reduction and a meaningful increase in risk.

Menopausal hormone therapy told a similar story. Drawing on eighteen studies, the pooled adjusted relative risk was 0.92, with a confidence interval of 0.79 to 1.06 that again crossed the threshold of no effect. Heterogeneity was even higher here, at 75.9 percent, and the prediction interval ranged from 0.54 to 1.56, once more signaling that results varied dramatically across populations and study designs. Estrogen therapy used alone, examined across six studies, yielded a pooled relative risk of 0.82 with a confidence interval of 0.63 to 1.07 — a point estimate hinting at a possible protective trend, but one that failed to reach statistical significance and was likewise graded as very-low-certainty evidence. For all three of these exposures, the adjusted analyses simply did not support a consistent link with pancreatic cancer.

The one exception emerged with estrogen–progestin therapy, the combined form of menopausal hormone therapy in which estrogen is paired with a progestin to protect the uterine lining. Across five studies, this regimen was associated with a modest but statistically robust inverse association: a pooled relative risk of 0.85, with a tight confidence interval of 0.78 to 0.93 and, remarkably, zero heterogeneity among the contributing studies. The prediction interval of 0.77 to 0.94 mirrored that consistency. This was the only finding in the adjusted analyses to achieve statistical significance, and it was graded as low-certainty evidence — a notch above the very-low ratings given to the other exposures, but still short of the certainty clinicians would want before drawing firm conclusions.

The biology behind such a signal is not far-fetched. Pancreatic ductal adenocarcinoma, the dominant form of the disease, expresses estrogen receptors and the G protein-coupled estrogen receptor, and experimental work has implicated estrogen signaling in pathways central to cancer cell behavior, including the PI3K/AKT and MAPK cascades, insulin-like growth factor signaling, and inflammatory and oxidative stress processes. Progestins, meanwhile, can modulate cell proliferation and differentiation. A modest protective effect of combined estrogen–progestin therapy is therefore biologically plausible, even if the observational nature of the evidence and the small number of contributing studies demand caution. Confounding by indication, differences in body mass index, smoking status, diabetes prevalence and other lifestyle factors across study populations could all shape the observed associations in ways that statistical adjustment cannot fully remove.

Indeed, the secondary crude analyses illustrated exactly how fragile such associations can be. When the researchers pooled unadjusted effect estimates instead of adjusted ones, they found substantially lower odds of pancreatic cancer among oral contraceptive users (an odds ratio of 0.70) and estrogen–progestin users (an odds ratio of 0.55). But both of these crude analyses were plagued by substantial heterogeneity and wide prediction intervals — the estrogen–progestin prediction interval stretched from 0.16 to 1.97 — suggesting that the apparent protection in crude data may partly reflect confounding by factors such as socioeconomic status, healthcare access, or healthier baseline profiles among hormone users rather than a genuine biological effect. The divergence between crude and adjusted results is a textbook demonstration of why observational hormone epidemiology is so treacherous.

The dose–response analyses added a further layer of nuance. Neither oral contraceptive use nor menopausal hormone therapy showed a significant linear relationship with pancreatic cancer risk per five-year increase in duration of use: the relative risks were 1.07 (p = 0.158) for the pill and 0.84 (p = 0.128) for menopausal hormone therapy. Non-linear models likewise failed to identify any significant threshold or U-shaped pattern. In other words, there was no evidence that taking hormones for longer periods progressively shifted risk in either direction, which weakens the case for a strong causal relationship and suggests that any real effects, if they exist, are likely to be modest and context-dependent.

The authors’ conclusions are measured and appropriately cautious. The adjusted evidence did not show a consistent association between oral contraceptive, menopausal hormone therapy, or estrogen therapy use and pancreatic cancer risk, and although estrogen–progestin therapy was linked to a modest reduction in risk, that finding rests on low-certainty observational evidence from only five studies. The wide prediction intervals for oral contraceptives and menopausal hormone therapy indicate that associations may vary across populations and settings, and the team explicitly calls for further large prospective studies to clarify the long-term hormonal effects on pancreatic carcinogenesis. For the millions of women weighing the risks and benefits of hormonal medications, the practical takeaway is largely reassuring: nothing in this comprehensive synthesis suggests that these widely used therapies meaningfully raise the risk of pancreatic cancer. And for researchers, the modest inverse signal from combined therapy offers a tantalizing, testable hypothesis — one that could ultimately illuminate how estrogen and progestin signaling shapes one of medicine’s most lethal tumors.

Subject of Research: The association between oral contraceptive and menopausal hormone therapy use and pancreatic cancer risk

Article Title: Oral contraceptive and menopausal hormone therapy use and risk of pancreatic cancer: a systematic review, meta-analysis, and dose–response analysis

Article References: Amouzadeh-Lichahi, M., Jafari, M., Sattari, N., Zamani, S., Letafatkar, N., & Ghodous, S. (2026). Oral contraceptive and menopausal hormone therapy use and risk of pancreatic cancer: a systematic review, meta-analysis, and dose–response analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16902-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16902-6

Keywords: pancreatic cancer, oral contraceptives, menopausal hormone therapy, estrogen therapy, estrogen–progestin therapy, meta-analysis, systematic review, dose–response analysis, observational studies, exogenous hormones, BMC Cancer, cancer epidemiology